Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Ruben A. Mesa, Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Janos Jakucs, Andrew Perkins, Ritam Prasad, Jiri Mayer, Judit Demeter, Peter Ganly, Jack W. Singer, Huafeng Zhou, James P. Dean, Peter A. te Boekhorst, Jyoti Nangalia, Jean Jacques Kiladjian, Claire N. Harrison

Research output: Contribution to journalArticlepeer-review

96 Scopus citations

Fingerprint

Dive into the research topics of 'Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases